Hard to Treat Diseases Inc. engages in the research, development, purchase, sale, and marketing of biological vaccines in China. It offers various vaccines, such as hepatitis A, hepatitis B, varicella, poliomyelitis, influenza virus, DTaP combined, meningococcal, and MMR combined vaccines. The company also provides other biological products, including refined tetanus antitoxin and cerebroprotein hydrolysate for injection. In addition, it offers API and injection products comprising meropenem for injection and Imipenem/Cilastatin sodium for injection. The company is based in Shenzhen, China.

Why this is a hot stock

- On Monday September 14, 2009 Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.

- According to health minister Chen Zhu “China will be able to produce enough influenza A(H1N1) vaccines for 65 million people by the end of this year.” (65 million is only about 5% of China’s 1.3 billion, population)